CARA Cara Therapeutics Inc
Price (delayed)
$0.2697
Market cap
$14.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.05
Enterprise value
$12.72M
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is
Highlights
The gross margin has increased by 13% year-on-year
Cara Therapeutics's EPS has increased by 9% from the previous quarter
Cara Therapeutics's equity has plunged by 89% YoY and by 61% from the previous quarter
The revenue has dropped by 60% year-on-year and by 35% since the previous quarter
Key stats
What are the main financial stats of CARA
Market
Valuations
Earnings
Shares outstanding
54.85M
Market cap
$14.79M
Enterprise value
$12.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.27
Price to sales (P/S)
1.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.16
Revenue
$11M
EBIT
-$106.59M
EBITDA
-$104.48M
Free cash flow
-$83.33M
Per share
Balance sheet
Liquidity
EPS
-$2.05
Free cash flow per share
-$1.52
Book value per share
$0.21
Revenue per share
$0.2
TBVPS
$1.32
Total assets
$72.5M
Total liabilities
$60.9M
Debt
$47.16M
Equity
$11.6M
Working capital
$49.96M
Debt to equity
4.07
Current ratio
4.59
Quick ratio
4.15
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
-950.2%
Gross margin
74.7%
Net margin
-1,010.2%
Operating margin
-1,000.1%
Return on assets
-110%
Return on equity
-241.3%
Return on invested capital
-165.5%
Return on capital employed
-181.9%
Return on sales
-969.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CARA stock price
How has the Cara Therapeutics stock price performed over time
Intraday
2.74%
1 week
-13%
1 month
-19.44%
1 year
-88.47%
YTD
-63.7%
QTD
4.53%
Financial performance
How have Cara Therapeutics's revenue and profit performed over time
Revenue
$11M
Gross profit
$8.21M
Operating income
-$109.97M
Net income
-$111.08M
Gross margin
74.7%
Net margin
-1,010.2%
CARA's net margin has dropped by 146% year-on-year and by 40% since the previous quarter
Cara Therapeutics's operating margin has plunged by 136% YoY and by 37% from the previous quarter
The revenue has dropped by 60% year-on-year and by 35% since the previous quarter
CARA's gross profit has plunged by 54% YoY and by 36% from the previous quarter
Growth
What is Cara Therapeutics's growth rate over time
Valuation
What is Cara Therapeutics stock price valuation
P/E
N/A
P/B
1.27
P/S
1.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.16
Cara Therapeutics's EPS has increased by 9% from the previous quarter
Cara Therapeutics's equity has plunged by 89% YoY and by 61% from the previous quarter
The P/B is 59% lower than the 5-year quarterly average of 3.0 but 3.3% higher than the last 4 quarters average of 1.2
CARA's P/S is 91% below its 5-year quarterly average of 14.5 and 50% below its last 4 quarters average of 2.6
The revenue has dropped by 60% year-on-year and by 35% since the previous quarter
Efficiency
How efficient is Cara Therapeutics business performance
Cara Therapeutics's ROS has plunged by 136% YoY and by 37% from the previous quarter
CARA's ROA has shrunk by 68% YoY and by 4.5% QoQ
CARA's return on invested capital is down by 42% year-on-year but it is up by 13% since the previous quarter
Cara Therapeutics's return on equity has decreased by 39% QoQ
Dividends
What is CARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CARA.
Financial health
How did Cara Therapeutics financials performed over time
The total assets is 19% more than the total liabilities
Cara Therapeutics's total liabilities has soared by 139% YoY
The total assets has decreased by 46% YoY and by 20% from the previous quarter
The company's debt to equity has surged by 168% QoQ
Cara Therapeutics's equity has plunged by 89% YoY and by 61% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.